Catheter Precision
Develops and commercializes electrophysiology products for cardiac arrhythmia treatment, including the VIVO 3D mapping system and LockeT vascular closure device.
- CEO / Founder
- David Jenkins
- Team Size
- 11-50
- Stage
- Public
- Total Funding
- $90.2M
- Latest Round
- Post-IPO
- Key Investors
- Hatteras Venture Partners; Safeguard Scientifics
Technology & Products
Key Products
VIVO; Amigo; LockeT
Technological Advantage
Catheter Precision's core advantage lies in its proprietary non-invasive 3D mapping system (VIVO) and vascular closure technology (LockeT), protected by a portfolio of issued and pending patents. The company has received FDA clearance for its products and is expanding international distribution. However, the technology is not specifically tied to additive manufacturing, and the company's primary business is medical devices, not AM.
Differentiation
Value Proposition
Provides non-invasive 3D cardiac mapping and vascular closure technologies that aim to improve procedural accuracy and patient outcomes while reducing reliance on invasive diagnostic methods.
How They Differentiate
Catheter Precision differentiates through non-invasive cardiac mapping (VIVO) and a novel vascular closure device (LockeT), targeting a niche in electrophysiology with a focus on ease of use and patient outcomes.
Market & Competition
Target Customers
Hospitals, electrophysiology labs, and clinicians treating cardiac arrhythmias
Industry Verticals
Medical Devices; Electrophysiology
Competitors
Medtronic; Abbott; Boston Scientific; Johnson & Johnson (Biosense Webster)
Growth & Milestones
Growth Metrics
2025 revenue reached $819 thousand, up 95% year over year; gross margin expanded.
Major Milestones
Merged with Ra Medical Systems in January 2023, becoming a public company (NYSE American: VTAK); Acquired 80.2% stake in Fly Flyte, Inc. in March 2026; Received FDA clearance for VIVO and LockeT products; Expanded distribution to Middle East in September 2024; Secured up to $88 million in strategic institutional financing commitments in March 2026
Notable Customers
St. David's Medical Center
Funding rounds
- Post-IPO$2.8M2026-07Source: Investing.com
- Post-IPO$88M2026-03Source: GlobeNewswire
- Post-IPO$36.5M2026-02Source: GlobeNewswire
- Post-IPO$3.47M2025-08Source: StockTitan
- Post-IPO$1.5M2025-05Source: GlobeNewswire